ALK and head and neck cancer: Conversely, we demonstrated that prediction of other clinically relevant features such as progression-free survival for squamous lung cancer and head and neck cancer, as well as genomic features such as certain driver mutations, ALK fusion status, and immune gene expression for certain cancers, are significantly driven by site-specific signatures—despite any form of normalization/augmentation.